Critical limb ischemia (CLI) is a manifestation of peripheral arterial disease (PAD), affecting nearly 2 million people in United States.[@b1]--[@b3] During PAD, arteries that supply blood to the legs are narrowed, typically due to atherosclerosis, and results in a number of symptoms called intermittent claudication. Patients with CLI have a 6-month risk of major amputation of 25% to 40% and an annual mortality of 20%.[@b4] Patients with CLI share the same traditional risk factors as patients with atherosclerosis in other vascular territories. Patients with CLI usually have concomitant severe cardiac (20%) and cerebrovascular disease (50% to 75%).[@b5]--[@b7] With an aging population and the rising incidence of diabetes and chronic kidney disease, the prevalence of CLI is likely to increase. Early recognition of PAD and aggressive risk factor modification is likely to ameliorate the severity of PAD presentation and will hopefully reduce the incidence of CLI.[@b8]

Hydrogen sulfide (H~2~S), historically viewed as an environmental toxic gas,[@b9]--[@b11] is now known to be an endogenous gaseous signaling molecule[@b12]--[@b16] that is required for the maintenance of normal vascular function. The production of H~2~S in mammalian systems has been attributed to at least 3 endogenous enzymes: cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), 3-mercaptopyruvate sulfur transferase (3-MST).[@b17]--[@b25] The rate of H~2~S production in tissue homogenates is in the range of 1 to 10 pmol/s per mg of protein, resulting in low micromolar extracellular concentrations.[@b26],[@b27] At this physiological concentration, H~2~S is cytoprotective in various models of cellular injury.[@b28],[@b29] As a gaseous signaling molecule, H~2~S diffuses across cell membranes in a receptor-independent manner and activates various cellular targets. This distinct ability makes H~2~S an attractive pharmacological agent for the treatment of cardiovascular disease. Recent evidence suggests that H~2~S is a mediator of many physiological and pathological processes.[@b13],[@b14],[@b16],[@b27],[@b30]--[@b39] While the exact mechanism of action of H~2~S is still under investigation, some chemical and biochemical catabolic reactions of H~2~S have been disclosed that may be responsible for its biological functions. This molecule provides significant protection in cardiac, neurologic, and hepatic models of ischemia reperfusion injury when delivered before an ischemic insult.[@b40]--[@b47] H~2~S dilates most mammalian blood vessels; the possibility that a deficiency in the biosynthesis of this gas contributes to or predisposes to cardiovascular diseases is appealing. Over the past few years, numerous other cardiovascular effects of H~2~S have been noted. These include proangiogenesis in vitro and in vivo,[@b48] positive vascular remodeling (ie, reduced vascular hyperplasia) in blood vessels of hypertensive rats,[@b49],[@b50] anti-atherosclerotic activity,[@b51] and reduced[@b52] binding of neutrophils to the blood vessel wall.

H~2~S is known to increase intracellular reduced glutathione concentrations and to suppress oxidative stress in mitochondria.[@b44] Coupled with the finding that mitochondria contain an H~2~S-producing enzyme, 3-MST is particularly interesting. The antioxidant activity of H~2~S may explain a number of the reported biological effects of this gas, including protection against (1) heart,[@b45] liver,[@b28] and intestinal[@b53] damage following ischemia/reperfusion injury; (2) H~2~O~2~-induced damage in rat gastric epithelial cells; (3) myocardial[@b54] and renal[@b55] injury due to hyperhomocysteinemia in rats; (4) methionine-induced[@b56] and homocysteine-induced[@b57] oxidative stress; and (5) hemin-mediated oxidation of low-density lipoprotein.[@b58] H~2~S is known to increase heme oxygenase 1 levels.[@b4],[@b59] Based on these facts, it is clear that H~2~S is a potent reducing agent and is likely to be consumed by endogenous oxidant species, such as peroxynitrite,[@b60] superoxide,[@b54] and H~2~O~2~.[@b61] Treatment with exogenous H~2~S or modulation of the endogenous production of H~2~S protects against acute myocardial ischemia/reperfusion injury and heart failure by attenuating oxidative stress, inhibiting apoptosis, and reducing inflammation.[@b4],[@b62] Recently, we have demonstrated that 1 mechanism by which H~2~S exerts cytoprotective actions is via upregulation of cellular antioxidants in a nuclear factor-erythroid-2-related factor 2 (NRF2)-dependent manner.[@b4] NRF2 regulates the gene expression of a number of enzymes that serve to detoxify pro-oxidative stressors,[@b63] by binding to the antioxidant response element (ARE) found in the gene-promoter region.[@b4] It is important to note here that most reactive oxygen species (ROS), such as superoxide, H~2~O~2~, lipid peroxides, and any other lipid radicals may not directly react with H~2~S but are presumably scavenged by either Cu, Zn-superoxide dismutase or catalase, and/or GPx1 or by their combined actions. On the other hand, H~2~S is known to activate NRF2 signaling, which is responsible for the upregulation of these antioxidant proteins.[@b4],[@b63]

The present study was undertaken to investigate the effects of CLI on endogenous levels of H~2~S, the expression of H~2~S-producing enzymes, and NRF2 and related downstream signaling pathways.

Materials and Methods
=====================

Collection of Skeletal Muscle From Human CLI and Healthy Controls
-----------------------------------------------------------------

Gastrocnemius tissues were attained from human CLI patients and otherwise healthy individuals (non-CLI) who underwent leg amputations. All patients were consented to the use of their amputated tissue for research purposes and signed a HIPPA release for use of the medical record. Patients were segregated into normal perfusion or CLI according to pulse examination and objective imaging criteria.

Institutional Review Board approval with consent was obtained.

Immunoblot Analysis
-------------------

Protein samples obtained from skeletal muscle of healthy controls and CLI patients were analyzed by immunoblotting[@b64] using specific antibodies to CBS (Santa Cruz), CSE (Abcam), 3-MST, thioredoxin-1 and -2 and thioredoxin reductase 1 and 2 (Santa Cruz), catalase (Santa Cruz), glutathione peroxidase-1 (Santa Cruz), NRF2 (Santa Cruz), fibrillarin (Cell Signaling), and GAPDH (Santa Cruz).

RNA Isolation and Reverse Transcriptase Real Time q-Polymerase Chain Reaction
-----------------------------------------------------------------------------

RNA was isolated from the skeletal muscle of CLI patients and healthy controls. One microgram of RNA was transcribed using an I-script cDNA synthesis kit from Bio-Rad. TaqMan primers for CBS, CSE, 3-MST, NRF2, TXN1 and 2, superoxide dismutase 1 and 2, catalase, and glutathione peroxidase-1 (GPx-1) from Life Technology were used to amplify q-polymerase chain reaction. For real-time q-polymerase chain reaction experiments, 18s was used as a housekeeping gene and values were corrected to 18s. 2^ΔΔCT^ was used for the data analysis of all q-polymerase chain reaction.[@b64]

Determination of Protein Carbonyl Content
-----------------------------------------

Protein carbonyl (CO) contents in skeletal muscle from CLI patients and healthy controls were measured as described previously.[@b65]

Measurement of MDA Levels
-------------------------

Malondialdehyde (MDA) levels in skeletal muscle from CLI patients and healthy controls were assayed as described previously.[@b65]

Measurement of H~2~S and Sulfane Sulfur
---------------------------------------

H~2~S and sulfane sulfur levels were measured in protein extracts from skeletal muscle of healthy controls and CLI patients by gas chromatography chemiluminescence.[@b66]

Electrophoretic Mobility Shift Assay
------------------------------------

Nuclear extracts (NE) were prepared from skeletal muscle of healthy controls and CLI patients. DNA-protein interaction was determined by utilizing electrophoretic mobility shift assay as described previously.[@b64]

Statistical Analysis
--------------------

All data in this study are expressed as the mean±SEM. Differences in data between the groups were compared using Prism 6 (GraphPad Software) with nonparametric test (Wilcoxon rank sum test). A *P* value of \<0.05 was considered statistically significant.

Results
=======

Decreased Levels of H~2~S and Sulfane Sulfur in Skeletal Muscle of CLI Patients
-------------------------------------------------------------------------------

H~2~S and sulfane levels were measured in samples obtained from skeletal muscle of CLI and healthy controls. As can be seen in [Figure 1](#fig01){ref-type="fig"}, both H~2~S (A) and sulfane sulfur (B) were significantly decreased in CLI patients as compared to control. Reduction in H~2~S (≈3-fold decrease) and sulfane sulfur may indicate reduced levels of H~2~S-producing enzymes such as CBS, CSE, and 3-MST in skeletal muscle of CLI patients.

![Levels of free H~2~S and sulfane sulfur in skeletal muscle of healthy controls and CLI patients. H~2~S and sulfane sulfur were measured in protein extracts obtained from skeletal muscle of CLI patients and aged-matched controls as described in Materials and Methods. H~2~S and sulfane sulfur are represented by (A) and (B), respectively. Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; H~2~S, hydrogen sulfide.](jah30004-e001986-f1){#fig01}

Reduction in the Levels of CBS, CSE, and 3-MST in Skeletal Muscle of CLI Patients
---------------------------------------------------------------------------------

Due to the decreased of levels H~2~S and sulfane sulfur in CLI patients, we next measured tissue levels of CBS, CSE, and 3-MST in skeletal muscle of CLI patients. Figures[2](#fig02){ref-type="fig"}A through [2](#fig02){ref-type="fig"}C and [3](#fig03){ref-type="fig"}A through [3](#fig03){ref-type="fig"}D show that both mRNA and protein levels of all 3 enzymes were significantly decreased in skeletal muscle of CLI patients, and it was clearly observed that the expression levels of CBS and CSE in CLI were reduced to about 2-fold or more as compared to control subjects. It is well appreciated that H~2~S increases cellular antioxidant levels.

![Expression of CBS, CSE, and 3-MST in skeletal muscle of healthy controls and CLI patients. A through C, represent the mRNA expression of CBS, CSE, and 3-MST genes, respectively, in the skeletal muscle of healthy controls and CLI patients. Circle with number inside bar denotes number of patients per group. CBS indicates cystathionine β-synthase; CLI, critical limb ischemia; CSE, cystathionine γ-lyase; 3-MST, 3-mercaptopyruvate sulfurtransferase.](jah30004-e001986-f2){#fig02}

![Levels of CBS, CSE, and 3-MST in skeletal muscle of control and CLI patients. A, Representative immunoblots of CBS, CSE, and 3-MST from either skeletal muscle of CLI patients or healthy controls. B through D, Represent relative intensity of immunoblots in (A). Circle with number inside bar denotes number of patients per group. CBS indicates cystathionine β-synthase; CLI, critical limb ischemia; CSE, cystathionine γ-lyase; 3-MST, 3-mercaptopyruvate sulfurtransferase.](jah30004-e001986-f3){#fig03}

Skeletal Muscle of CLI Patients Shows Decreased NRF2 Activity
-------------------------------------------------------------

NRF2 is a nuclear factor that binds to the ARE site in a specific promoter and thereby enhances the transcription of antioxidant protein genes. It was of next interest to determine the NRF2 activity in skeletal muscle of CLI patients. [Figure 4](#fig04){ref-type="fig"}A shows mRNA of NRF2 was markedly decreased in skeletal muscle of CLI patients as compared to control subjects. Nuclear level of NRF2 was also found to be decreased significantly (≈2-fold) in CLI patients compared to control subjects ([Figure 4](#fig04){ref-type="fig"}B and [4](#fig04){ref-type="fig"}C). DNA binding activity of NRF2 to consensus ARE site was analyzed using electrophoretic mobility shift assay. [Figure 4](#fig04){ref-type="fig"}D shows that NRF2-DNA binding activity was markedly decreased in nuclear extracts of skeletal muscle of CLI patients as compared to control subjects. [Figure 4](#fig04){ref-type="fig"}E represents the binding specificity of NRF2 to ARE site.

![Activity of NRF2 in skeletal muscle of CLI patients. A, Represents mRNA expression of NRF2 in the skeletal muscle of control and CLI patients. B, Represents immunoblots of nuclear levels of NRF2 and fibrillarin in the skeletal muscle of control and CLI patients. C, Quantitation of immunoblots in (B). D, NRF2-DNA binding activity as judged by EMSA; lanes 1 and 2, control; lanes 3 and 4, CLI. E, The binding specificity of NRF2; lane 1, free probe; lane 2, NE; lane 3, NE+W/T oligo (250× excess); lane 4, NE+NRF2 antibody; and lane 5, NE+nonspecific antibody (non sp. ab). Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; EMSA, electrophoretic mobility shift assay; NE, nuclear extracts; NRF2, nuclear factor-erythroid 2-related factor 2; W/T, wild type.](jah30004-e001986-f4){#fig04}

Induction of Oxidative Stress in Skeletal Muscle of CLI Patients
----------------------------------------------------------------

One of the pathological consequences of chronic tissue ischemia is increased oxidative stress and cellular injury. Therefore, it was of interest to determine the levels of oxidative stress in the protein samples obtained from skeletal muscle of CLI patients. Oxidative stress was measured by determining the levels of protein CO contents and MDA formation. As can be seen in [Figure 5](#fig05){ref-type="fig"}A and [5](#fig05){ref-type="fig"}B, both protein CO contents and MDA were significantly increased in skeletal muscle of CLI patients as compared to control subjects. Protein CO contents and MDA are considered biomarkers of oxidative stress; therefore, based on the induction of protein CO (≈2-fold) and MDA (≈2-fold) formation in skeletal muscle of CLI patients, these data suggest that the cellular oxidative stress is increased in CLI patients.

![Induction of oxidative stress in skeletal muscle of CLI patients. Biomarkers of oxidative stress such as protein CO contents (A) and MDA (B) formation were significantly increased in skeletal muscle of CLI patients as compared with healthy controls. Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; CO, carbonyl; MDA, malondialdehyde.](jah30004-e001986-f5){#fig05}

Skeletal Muscle of CLI Patients Exhibits Reduced Levels of Antioxidant Proteins
-------------------------------------------------------------------------------

We next determined the levels of antioxidant proteins in skeletal muscle of CLI patients. We determined both mRNA and protein levels of antioxidant protein in skeletal muscle of CLI patients as well as in control subjects. As can be seen in [Figure 6](#fig06){ref-type="fig"}, significant reductions (≈2-fold) in mRNA expression of catalase (A), glutathione peroxidase-1 (GPx-1) (B), and Cu, Zn-superoxide dismutase (SOD1) (C) were observed in skeletal muscle of CLI patients as compared to control subjects. Immunoblot analysis demonstrated significant reduction in protein levels of GPx-1 and superoxide dismutase in skeletal muscle of CLI patients as compared to control ([Figure 7](#fig07){ref-type="fig"}A, [7](#fig07){ref-type="fig"}C, and [7](#fig07){ref-type="fig"}D). These data clearly demonstrate reduced expression of antioxidant enzymes results in CLI patients in addition to increased levels of oxidative stress.

![Decreased expression of antioxidant gene in skeletal muscle of CLI patients. A through D, Represent the mRNA expression of catalase, GPx-1, SOD1, and SOD2, respectively, in the skeletal muscle of control and CLI patients. Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; GPx-1, glutathione peroxidase-1; NS, not significant; SOD1, Cu, Zn-superoxide dismutase.](jah30004-e001986-f6){#fig06}

![Antioxidant protein levels in skeletal muscle of healthy controls and CLI patients. A, Immunoblots for the levels of Cat, GPx-1, SOD1 and SOD2 of the skeletal muscle of CLI patients and healthy controls. B through E, Quantitation of immunoblots in (A). Circle with number inside bar denotes number of patients per group. Cat indicates catalase; CLI, critical limb ischemia; GPx-1, glutathione peroxidase-1; NS, not significant; SOD1, Cu, Zn-superoxide dismutase; SOD2, Mn-superoxide dismutase.](jah30004-e001986-f7){#fig07}

Decreased Levels of Thioredoxins and Thioredoxin Reductases in Skeletal Muscle of CLI Patients
----------------------------------------------------------------------------------------------

Thioredoxins are proteins that act as antioxidants by facilitating the reduction of other proteins by cysteine thiol-disulfide exchange. Thioredoxin plays a central role in humans and is increasingly linked to medicine through their response to ROS. In order to define the roles of thioredoxins in CLI patients, both mRNA and protein levels of thioredoxin 1 and 2 were analyzed. As can be seen in [Figure 8](#fig08){ref-type="fig"}A through [8](#fig08){ref-type="fig"}E, both mRNA and protein levels of thioredoxin 1 and 2 significantly decreased in CLI patients as compared to healthy control subjects. Furthermore, an experiment was also performed to analyze the expression of thioredoxin reductase 1 and 2. Thioredoxin reductases catalyze the NADPH-dependent reduction of thioredoxin 1 and 2 and other oxidized cellular components and thereby prevent cellular oxidative damage. [Figure 9](#fig09){ref-type="fig"}A and [9](#fig09){ref-type="fig"}B shows that mRNA expression of thioredoxin reductases 1 and 2 were significantly decreased in skeletal muscle of CLI patients as compared to control subjects.

![Levels of TXN1 and 2 in skeletal muscle of healthy controls and CLI patients. A and B, Represent the mRNA expression of TXN1 and TXN2, respectively, in the skeletal muscle of control and CLI patients. C, Immunoblots of TXN1 and TXN2 for the protein samples obtained from skeletal muscle tissues from CLI patients and controls. D and E, Quantitation of immunoblots in (C). Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; TXN, thioredoxin.](jah30004-e001986-f8){#fig08}

![Expression of TXNRD1 and TXNRD2 in CLI patients. A and B, Represent the mRNA expression of TXNRD1 and TXNRD2 in CLI patients and healthy controls. Circle with number inside bar denotes number of patients per group. CLI indicates critical limb ischemia; TXNRD, thioredoxin reductase.](jah30004-e001986-f9){#fig09}

Discussion
==========

In the present study, we provide novel insights into the biochemical and molecular derangements in isolated skeletal muscle in the setting of CLI. The major finding of this study is that the pathological conditions occurring in chronic CLI decrease H~2~S bioavailability and expression of H~2~S-producing enzymes in CLI patients. Furthermore, we have determined that NRF2 activity is also significantly attenuated in CLI patients as compared to control subjects. Uncontrolled oxidative stress resulting in decreased H~2~S bioavailability and attenuated NRF2 activity may significantly contribute to the pathogenesis of CLI. Therapies aimed at restoring redox balance, thereby increasing H~2~S, may prove beneficial for the treatment of CLI.

H~2~S is synthesized in tissues throughout the body by enzymes located either in the cytosol (CBS, CSE) or in mitochondria (3-MST). Because H~2~S is a highly diffusible gas, upon formation it is likely to be either sequestered or catabolized rapidly. The molecular targets for H~2~S are largely unknown, but recent experimental studies suggest that H~2~S impacts on intracellular proteins, enzymes, transcription factors, as well as an array of membrane ion channels. H~2~S produces anti-apoptotic, anti-inflammatory, antihypertrophic, cardioprotective, and anti-oxidant effects, which ultimately can lead to protection from cellular injury or oxidative damage. H~2~S is also known to have protean effects, including the regulation of inflammation, vascular permeability and tone, and cellular metabolism. H~2~S also activates prosurvival signaling cascades such as the reperfusion injury salvage kinases, which include PI3-kinase/Akt and extracellular signal-regulated kinase, among others.[@b2],[@b67] Previous studies clearly demonstrate that H~2~S-releasing drugs significantly limit myocardial ischemia/reperfusion injury and myocardial injury in heart failure.[@b2],[@b4],[@b68],[@b69]

A major mechanism by which H~2~S exerts cytoprotective actions is via upregulation of cellular antioxidants in an NRF2-dependent manner.[@b4] In addition, H~2~S markedly reduces cellular ROS levels and suppresses oxidative stress in mitochondria via increasing intracellular reduced glutathione concentration.[@b44] Furthermore, mitochondria are able to synthesize H~2~S via 3-MST and thereby regulate redox balance and oxidant stress within the mitochondria.[@b44] Significant increases in oxidative stress that overwhelm endogenous antioxidant defenses result in potentially cytotoxic reactions with membrane phospholipids, proteins, nucleic acids, and other cellular components, and ultimately impair cell structure and function, leading to cell damage. In the present study, we determined that H~2~S bioavailability was significantly reduced in the skeletal muscle of CLI patients. We also observed significant reductions in the protein expression of the H~2~S-producing enzymes in CLI skeletal tissue. It is well appreciated that H~2~S leads to NRF2 activation,[@b70],[@b71] which attenuates oxidative damage by increasing the levels of antioxidant proteins. Previous reports have indicated that NRF2 deficiency is associated with enhanced oxidative stress and cell death.[@b72],[@b73] NRF2 is a family of nuclear basic leucine zipper transcription factors that regulate the gene expression of a number of antioxidant enzymes that serve to detoxify pro-oxidative stressors[@b63] including GPx-1 and heme oxygenase 1.[@b4] NRF2 is widely expressed and is thought to translocate to the nucleus after treatment with xenobiotics and antioxidants, which stimulate its release from a repressor protein Kelch-like ECH (enoyl-CoA hydratase)-associated protein 1. Following translocation into the nucleus, NRF2 binds the ARE site in the promoter region of a gene and enhances the transcription of antioxidant proteins, which results in suppression of an oxidative stress response. Therefore, NRF2 controls the basal and inducible expression of antioxidant genes and other cytoprotective phase II detoxifying enzymes that are ubiquitously expressed throughout the cardiovascular system. Emerging evidence has revealed that NRF2 and its target genes are critical regulators of cardiovascular homeostasis via the suppression of oxidative stress/ROS production.[@b74] Similarly, oxidative stress/reactive oxygen species may also potentiate development of CLI.

In the present study, we found a significant induction of oxidative stress in skeletal muscle of CLI patients compared to controls, as judged by measuring the levels of protein CO contents and MDA formation (as protein CO contents and MDA formation are considered biomarkers of oxidative stress). Under basal conditions, the ability of NRF2 to induce endogenous antioxidants is tightly regulated when anchored in the cytoplasm, and is targeted for ubiquitination and proteasome degradation.[@b75] Only when there is a disruption in the binding of NRF2 to the cytosolic anchoring proteins (such as Kelch-like ECH-associated protein 1) is NRF2 able to translocate to the nucleus and protect the cells from oxidative damage through enhancing the transcription of antioxidant genes. Previous studies have indicated that H~2~S exerts cytoprotective actions through upregulation of cellular antioxidants via the NRF2 signaling pathway.[@b4]

Medical management of CLI entails pain control, risk factors modification, proper wound care, and infection management. The management of this complex patient population often warrants a multidisciplinary approach with collaboration with an endovascular interventionist, vascular surgeons, podiatrist, infectious disease specialist, and wound-care specialist. Although data are limited, with regard to pharmacological interventions in CLI patients, most of the pharmacological measures are of proven benefit in reducing the risk of death, myocardial infarction, heart failure, and stroke in patients with atherosclerosis, and therefore the use of such therapy, despite the lack of evidence in the setting of CLI, is justified to limit adverse cardiovascular events.[@b76]--[@b82] Various reports have demonstrated that the use of "cardioprotective" medications such as statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and antiplatelet agents is associated with a decreased cardiovascular event rate in patients with PAD.[@b77] However, little is known about the effectiveness of these drugs in patients with CLI. Effective new treatments for CLI are critically important, given the high incidence of major amputation and mortality seen in this population.[@b83] Increasing blood flow, tissue perfusion, and oxygen and nutrient delivery via new vessel growth (ie, angiogenesis) or collateralization could promote tissue regeneration, and/or delay or even prevent tissue necrosis and the development of conditions such as gangrene.

In the present study, we observed that levels of H~2~S and H~2~S-producing enzymes were significantly decreased in skeletal muscle of CLI patients as compared to healthy controls. We also found significant reductions in NRF2 activation and antioxidant proteins concomitant with increased skeletal muscle oxidative stress in CLI patients. In conclusion, the present study clearly demonstrates that induction of oxidative stress and attenuated NRF2 signaling appears to be involved in the pathogenesis of CLI and is associated with significant reductions in skeletal muscle H~2~S bioavailability. Given the recent elucidation of the potent cytoprotective, antioxidant, and pro-angiogenic properties of physiological or pharmacological levels of H~2~S, it is possible that H~2~S-based therapies or H~2~S-induced NRF2 activation may prove beneficial for the treatment of CLI. In the present study, we examined a small sample of control tissues, which represents a limitation of this research. However, it is very difficult to obtain these skeletal muscle samples from otherwise healthy individuals undergoing limb amputations. Clearly, additional studies of CLI in clinically relevant models are required to validate the therapeutic effects of H~2~S in this devastating disease.
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